Daiichi Sankyo

Astellas stays ahead of its FLT3 rivals with EU nod for Xospata

Meanwhile, Daiichi Sankyo has said it will concentrate on first-line use of quizartinib after being turned down by regulators in Europe and the US, and says it recently completed enrolment ... There are differences between the two drugs, as quizartinib

Seattle Genetics preps filing next year for oral HER2 drug

Competition in the HER2 category is heating up though, with a new antibody-drug conjugate from Daiichi Sankyo and AstraZeneca –  trastuzumab deruxtecan – angling for approval in the US in the second

AZ and Daiichi get speedy review for rival to Roche’s HER2 drugs

Could add to AZ's portfolio of emerging cancer drugs. AstraZeneca and Daiichi have picked up a priority review from the FDA for their breast cancer therapy trastuzumab deruxtecan, setting up ... Analysts’ expectations for sales potential vary,

Leading AstraZeneca’s return to growth in Europe

Looking to build its momentum in oncology even further, AstraZeneca recently signed a huge $6.9bn deal with Daiichi-Sankyo to develop and co-market its next-generation challenger to

Astellas’ Xospata scores positive CHMP recommendation

The positive recommendation puts Astellas even further in the lead in front of Daiichi Sankyo – its candidate for FLT3-positive AML was rejected by the FDA earlier this year following misgivings

[ Previous 5 results ] 1 2 3 4 5 6 7 8 9 10 [ Next 5 results ]